Drugs / Tiragolumab
Trials 65 · started per year
today
1
3
2
5
10
9
7
17
4
7
2017201820192020202120222023202420252026
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06760481 | Apr 2025 → Sep 2028 expected | high grade malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05259319 | Dec 2022 → Dec 2024 | head and neck cancer, non-small cell lung carcinoma, renal cell carcinoma, urinary bladder cancer | Centre Georges Francois Leclerc | Unknown | No outcome recorded |
| Phase 1 | NCT04929223 | Oct 2021 → Aug 2030 expected | colorectal cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT04584112 | Sep 2020 → Mar 2023 | triple-negative breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04045028 | Jul 2019 → Mar 2023 | non-Hodgkin lymphoma, plasma cell myeloma | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02794571 | May 2016 → Nov 2024 | metastatic neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/214 trials | ||||||
| Phase 1/2 | NCT05908786 | Dec 2023 → Aug 2025 | hepatocellular carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT05743504 | Sep 2023 → May 2025 | esophageal squamous cell carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05459129 | Apr 2023 → Aug 2024 | head and neck squamous cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT05394337 | Feb 2023 → Dec 2028 expected | metastatic malignant neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05286801 | Nov 2022 → Mar 2030 expected | atypical teratoid rhabdoid tumor, epithelioid sarcoma, high grade malignant neoplasm, kidney medullary carcinoma +1 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05315713 | May 2022 → Jul 2023 | follicular lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT05251948 | Mar 2022 → Sep 2025 | gastroesophageal cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT05116202 | Feb 2022 → Sep 2023 | melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT04486352 | Oct 2021 → Oct 2026 expected | endometrial cancer | Alliance Foundation Trials, LLC. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04524871 | Nov 2020 → Jul 2027 expected | liver cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03869190 | Jun 2019 → Oct 2025 | urinary bladder cancer, urothelial carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT03337698 | Dec 2017 → Oct 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT03281369 | Oct 2017 → Oct 2025 | digestive system carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT03193190 | Jul 2017 → Feb 2025 | pancreatic adenocarcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 235 trials | ||||||
| Phase 2 | NCT06603818 | Aug 2025 | colorectal cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT07038915 | Jul 2025 | squamous cell lung carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT06328036 | Apr → Jul 2025 | IDH-wildtype glioblastoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT06754501 | Apr 2025 → Jul 2027 expected | cancer | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06784947 | Mar → Sep 2025 overdue | colorectal cancer | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06713798 | Jan → Sep 2025 | lung cancer | Gustave Roussy, Cancer Campus, Grand Paris | Withdrawn | No outcome recorded |
| Phase 2 | NCT06331598 | Nov 2024 → Oct 2028 | cancer | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 2 | NCT06342037 | Jun 2024 → Apr 2026 overdue | breast cancer | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06175390 | Mar 2024 → Aug 2026 overdue | triple-negative breast carcinoma | Institut Curie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06003621 | Dec 2023 → May 2026 overdue | cancer | Omico | Recruiting | No outcome recorded |
| Phase 2 | NCT05798663 | Dec 2023 → Nov 2026 expected | non-small cell lung carcinoma | Alliance Foundation Trials, LLC. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05483400 | Oct 2023 → Sep 2025 overdue | head and neck neoplasm, melanoma | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase 2 | NCT05715281 | Sep 2023 → Oct 2025 overdue | high grade malignant neoplasm, refractory malignant neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05746481 | Aug 2023 → Aug 2024 | non-small cell lung carcinoma | Liza Villaruz, MD | Terminated | No outcome recorded |
| Phase 2 | NCT05681039 | Jun 2023 → Nov 2026 expected | oral cavity squamous cell carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05825625 | May 2023 → Dec 2026 expected | non-small cell lung carcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05661578 | May 2023 → Dec 2025 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT05805501 | Apr 2023 → Oct 2026 expected | renal cell carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05645692 | Apr 2023 → Dec 2026 expected | urothelial carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05661188 | Feb 2023 → Jun 2027 expected | anal canal squamous cell carcinoma | Grupo Espanol Multidisciplinario del Cancer Digestivo | Recruiting | No outcome recorded |
| Phase 2 | NCT05060003 | Nov 2022 → Nov 2023 | melanoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT05009069 | Mar 2022 → Nov 2023 overdue | rectal cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04958811 | Dec 2021 → Jul 2026 overdue | non-small cell lung carcinoma | Georgetown University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04308785 | Dec 2021 → Jul 2023 | small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 2 | NCT05034055 | Dec 2021 → Dec 2023 | non-small cell lung carcinoma | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT04933227 | Aug 2021 → Nov 2023 | gastric cancer, gastroesophageal junction adenocarcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 2 | NCT04832854 | Apr 2021 → Mar 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 2 | NCT04665843 | Mar 2021 → Sep 2023 | head and neck squamous cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT04632992 | Jan 2021 → Dec 2023 | cancer of unknown primary site | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04300647 | Jun 2020 → Dec 2021 | cervical cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT03977467 | Aug 2019 → Aug 2024 | non-small cell lung carcinoma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03708224 | Mar 2019 → Jun 2028 expected | head and neck cancer, squamous cell carcinoma | Alain Algazi | Recruiting | No outcome recorded |
| Phase 2 | NCT03784326 | Feb 2019 → Dec 2026 expected | esophageal adenocarcinoma, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03554083 | Oct 2018 → Apr 2025 | cutaneous melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03563716 | Aug 2018 → Jun 2019 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04619797 | Dec 2020 → Apr 2024 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT06267001 | Mar 2024 → Dec 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT05904886 | Sep 2023 → May 2025 overdue | hepatocellular carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05862285 | Jun 2023 → Mar 2033 expected | cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT04665856 | Dec 2020 → Aug 2023 overdue | small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04540211 | Oct 2020 → Feb 2023 | esophageal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04543617 | Sep 2020 → Mar 2027 expected | esophageal squamous cell carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04513925 | Aug 2020 → May 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04294810 | Mar 2020 → Dec 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04256421 | Feb 2020 → Sep 2022 | small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-10 | Roche Global Development | New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq roche.com ↗ |
| 2021-01-05 | Roche Global Development | Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer roche.com ↗ |
| 2020-05-14 | Roche Global Development | Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO roche.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 68 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tiragolumab | “All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy” NCT05661188 ↗64“four cycles of 1200 mg of atezolizumab (Tecentriq®, Roche) and 600 mg of Tiragolumab (Roche) every 3 weeks” NCT06175390 ↗ |
| Known as | MTIG-7192A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298050 ↗ |
| Known as | RG-6058 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298050 ↗ |
| Known as | RO-7092284 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298050 ↗ |
| Known as | Tira | “Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated...” NCT03869190 ↗1“This study evaluated the safety and efficacy of atezolizumab (Atezo) with or without tiragolumab (Tira) after nCRT in patients with LARC.” PMID 41529226 ↗ Jan 2026 |
| Action | Inhibit | “that blocks the binding of TIGIT to CD155” PMID 38105505 ↗ Jan 2024 |
| Modality | Monoclonal antibody | “Tiragolumab is a first-in-class, fully human IgG1/kappa anti-TIGIT monoclonal antibody” PMID 38105505 ↗ Jan 2024 |
| Route | Intravenous | “Tiragolumab will be given via IV infusion” NCT02794571 ↗ |
| Target | TIGIT | “Tiragolumab is a first-in-class, fully human IgG1/kappa anti-TIGIT monoclonal antibody that blocks the binding of TIGIT to CD155” PMID 38105505 ↗ Jan 2024 |